论文部分内容阅读
目的研究接种黄热病疫苗(YFV)的同时接种甲肝疫苗(该疫苗用流感病毒作佐剂的疫苗即IRIV-HAV)后,受种人的耐受力及可能产生的免疫力。方法有两个对比组共105名自愿参加受试者。研究抗甲肝病毒抗体反应效果。53个接种1次IRIV-HAV(Epaxal)疫苗及在同1天不同部位接种1次YTV疫苗(stamaril)。另56人只接种1次IRIV-HAV作对比组。分别在接种后14天,28天,3个月,12个月,13个月,24个月用标准酶标法测试,测定甲肝抗体效价。黄热病疫苗抗体效价测试时间分别在14天,28天以作对比。观察受种人耐受力,询问有何不良反应,作好记录。结果甲肝血清阳转率14天后88%,4周后达100%,两组每次测验的效价比(IRIV-HAV:HAV)分别是14天为81:101,28天为275:368,3个月为153:169,12个月为117:226,均是几何平均效价值(GMT)inmlu/ml,统计学上无显著性差异。但男性受种人有低效价值出现。该男性不予接种YFV疫苗。接种YFV疫苗后14天血清阳转率达90%,4周后达96%无全身不良反应,仅有局部反应。12个月激发免疫接种IRIV-HAV,GMT呈24倍增加。结论同时接种IRIV-HAV和YFV疫苗可产生免疫力,安全,受种人易接受,对上述两种抗原均有反应,无交叉干扰。
Objective To investigate the tolerability and potential immunity of humans after vaccination with the yellow fever vaccine (YFV) while vaccinated with the hepatitis A vaccine (IRIV-HAV adjuvanted with the vaccine). METHODS: A total of 105 volunteers from two control groups voluntarily participated in the study. Study anti-hepatitis A virus antibody response. Fifty-three vaccinated with the IRIV-HAV (Epaxal) vaccine and inoculated with 1 YTV vaccine (stamaril) at different sites on the same day. Another 56 people were vaccinated with IRIV-HAV only once as control group. The antibody titers of HAV were measured by standard enzyme labeling method at 14 days, 28 days, 3 months, 12 months, 13 months and 24 months after inoculation. Yellow fever vaccine antibody titer test at 14 days, 28 days for comparison. Observe endurance, ask about any adverse reactions, make a note. Results The seroconversion rate of hepatitis A was 88% after 14 days and 100% after 4 weeks. The titer of IRIV-HAV: HAV for each test was 81: 101 for 14 days, 275: 368 for 28 days, The month was 153: 169, and the 12 months was 117: 226, both of which were in geometric mean (GMT) inmlu / ml, with no statistically significant difference. However, men are ineffective by the value of their species. The man is not vaccinated against YFV. The seroconversion rate was 90% at 14 days after vaccination with YFV vaccine and 96% after 4 weeks without systemic adverse reactions, with only local reactions. After 12 months of immunization with IRIV-HAV, GMT showed a 24-fold increase. Conclusions Simultaneous inoculation of IRIV-HAV and YFV vaccines can produce immunity, safety and acceptability by human beings, and respond to both antigens without cross-interference.